Bolt Biotherapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Bolt Biotherapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.70M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $7.69M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $7.88M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $5.73M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.26M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $231.0K | Mar 30, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.38M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($63.12M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($69.20M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($88.10M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($98.59M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($60.73M) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.11M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($73.05M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($76.20M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($90.32M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($92.79M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($49.18M) | Mar 30, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.53M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $57.47M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $61.54M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $73.12M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $75.66M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $40.36M | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.85M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($61.29M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($69.53M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($76.50M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($57.07M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($47.31M) | Mar 30, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $41.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $206.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.95M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $2.34M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $3.26M | Mar 30, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.75M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $99.63M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $159.78M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $227.81M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $307.72M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $46.54M | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.24M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $42.43M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $47.04M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $56.30M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $57.60M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $46.19M | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.51M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $57.20M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $112.74M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $171.51M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $250.12M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($104.95M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | ($45.85M) | Mar 30, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($460.78M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($427.40M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($364.29M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($295.09M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($206.99M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($108.40M) | Mar 30, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.70M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $7.21M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $10.81M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $9.24M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $27.38M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $5.54M | Mar 30, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (17) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (33) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (17) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (33) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 29, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.92M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 1.92M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 38.11M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 37.80M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 37.40M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 2.13M | Mar 30, 2022 |